Europe Genital Warts Market – Industry Trends and Forecast to 2029

Europe Genital Warts Market Analysis and Size

The Europe genital warts market is expected to witness significant growth during the forecast period. Genital warts are caused because of the human papillomavirus (HPV). There are about 30-40 strains of HPV. As per the records of the World Health Organization (WHO) 2019, more than 1 million sexually transmitted infections (STIs) are acquired each day globally and more than 290 million women attain a human papillomavirus (HPV) infection. Recurrence of warts rises the demand for more advanced treatment. Several treatments are available for warts. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the Europe genital warts market in the forecast period 2022-2029. The expected CAGR of Europe genital warts market is tend to be around 6.70% in the mentioned forecast period. The market was valued at USD 1,519.14 million in 2021, and it would grow upto USD 2552.19 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Genital warts are one of the most recurrent kinds of sexually transmitted infections. HPV is the virus that is responsible for causing genital warts. People are likely to get infected with at least one type of human papillomavirus (HPV). Genital warts affect most moist tissues in the genital areas of male and female patients. Even though the genital infection is asymptomatic, it is frequently recognized as genital warts due to the onset of symptoms. It is projected that about 1% of sexually active men and women in the U.S. have genital warts.

Europe Genital Warts Market Scope and Segmentation

Europe Genital Warts Market Dynamics

Drivers

• Increased Cases of STI

The increasing prevalence of sexually transmitted infections (STIs) is expected to boost the market's growth. Around 38.4 million people were globally living with STI at the end of 2021. According to the WHO 2019, more than 1 million sexually transmitted infections (STIs) are acquired each day globally and more than 290 million women have a human papillomavirus (HPV) infection. Thus, these higher number of infections boost the market growth.

• Rising Incidence of Cervical Cancer

The number of cervical cancer rates are high in many underdeveloped countries, where more than 80% of cervical cancer cases are diagnosed. According to the WHO, cervical cancer is the most common type of malignancy in women and the second leading cause of cancer-related death globally, responsible for over 300,000 fatalities per year. This boosts the market growth.

Opportunities

• New Treatment Launches by Market Players

Market players are involved in launching new treatment platforms that are expected to increase the growth of the Europe genital warts market during the forecast period. For instance, in 2019, GenieMD, which is a global provider of telemedicine services, launched their telemedicine app iVisit that would allow the diagnosis and treatment of patients for genital warts through virtual visit with the physician.

• Increasing Demand for Retail Pharmacies

The rise in cervical cancer led to the delivery of drugs through retail pharmacies, creating a surge in the number of retail pharmacies in highly developed countries. In addition, patients choose retail pharmacies to purchase drugs, as these are easily accessible.

• Increased Research and Development

Growing R&D in order to develop treatment for genital warts is projected to increase the growth of the global genital warts market during the forecast period. For instance, University of Pretoria, South Africa, in collaboration with University of Stellenbosch, South Africa, are currently conducting clinical trials to study the effectiveness of human papillomavirus (HPV) vaccine against the existence of genital warts. The study was started in the year 2018 and is projected to be completed by 2023. At present, the study is in the Phase III clinical trial.

 Restraints/Challenges

• Lack of Awareness

Even though the occurrence of genital warts is high among the population, but its diagnosis rate is still low. The low diagnostic rate of genital warts is because of the lack of awareness about the infection, which may impede the genital warts market growth. For instance, as per the Health Protection report in 2018, the diagnosis rate of genital warts in England among girls aged 15 to 17 decreased by 92% compared to 2014. Furthermore, existing treatment procedures are often painful or invasive and can have unfavorable outcomes such as scarring or dyspigmentation, often requiring frequent visits. This results in a reduction in the diagnostic rate, likely restraining the genital warts market.

• High Cost

The huge expenditure associated with infection drugs, gels, or severe treatment procedures hamper market growth.

This Europe genital warts market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe genital warts market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Europe Genital Warts Market       

COVID-19 pandemic has benefited the global human papillomavirus infection drugs market positively. Even though there was lockdown and many of the tasks were in consideration with COVID-19, most healthcare workers are carrying out their tasks, and companies are spending greatly in vaccine development for HPV.

The bigger population demand for HPV vaccine is likely to boost the market during a pandemic. Vaccine manufacturers and other scientists are working continuously on the development of HPV vaccines as well as COVID viral symptoms, which is predicted to boost the market in the next years.

Europe Genital Warts Market Scope

The Europe genital warts market is segmented on the basis of morphology, prevention, cause, location, gender, dosage, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Morphology

• Cauliflower-Like
• Smooth Papular
• Keratotic
• Flat Warts

Prevention

• Prevention
• Diagnostics
• Treatment

Cause

• HPV 6
• HPV 11
• Others

Location

• Vulva
• Cervix Uteri
• Urethra
• Anus
• Scrotum

Gender

• Male
• Female

Dosage

• Cream
• Gel
• Ointment
• Intramuscularly
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Europe Genital Warts Market Regional Analysis/Insights

The Europe genital warts market is analyzed and market size insights and trends are provided by morphology, prevention, cause, location, gender, dosage, distribution channel and end-user as referenced above.

The major countries covered in the Europe genital warts market report are Germany, France, Italy, Belgium, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.

Germany is expected to dominate the market due to the presence of major market players and increased technological advancement in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Europe Genital Warts Market Share Analysis

The Europe genital warts market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe genital warts market.

Key players operating in the Europe genital warts market include:

• Bausch Health Companies Inc (Canada)
• Merck & Co., Inc (U.S.)
• Taro Pharmaceutical Industries Ltd (Israel)
• CryoIQ (Sweden)
• GSK plc (U.K.)
• BioNTech SE (Germany)
• Serum Institute of India Pvt. Ltd (India)
• Fotona (U.S.)
• Orgenesis Inc (U.S.)
• Perrigo Company plc (Ireland)

SKU-64296